Colistin dosing and nephrotoxicity in a large community teaching hospital - PubMed

C Andrew Deryke 1 , Amanda J Crawford, Nizam Uddin, Mark R Wallace

Article Images

Colistin dosing and nephrotoxicity in a large community teaching hospital

C Andrew Deryke et al. Antimicrob Agents Chemother. 2010 Oct.

Abstract

Thirty adult patients who received intravenous colistin (5.1 ± 2.4 mg/kg/day) were reviewed to evaluate dosing with respect to nephrotoxicity, which occurred in 10 (33%) patients within the first 5 days of treatment. Excessive colistin dosing was frequent (47%), often (71%) resulted from the use of actual body weight in obese patients, and was associated with higher rates of nephrotoxicity (80% versus 30%, P = 0.019).

PubMed Disclaimer

Cited by

Nephrotoxicity caused by colistin use in ICU: a single centre experience.
Kilic I, Ayar Y, Ceylan İ, Kaya PK, Caliskan G. Kilic I, et al. BMC Nephrol. 2023 Oct 13;24(1):302. doi: 10.1186/s12882-023-03334-8. BMC Nephrol. 2023. PMID: 37833622 Free PMC article.
Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections.
Simon V, Viswam A, Alexander PS, James E, Sudhindran S. Simon V, et al. Indian J Pharmacol. 2023 Jul-Aug;55(4):229-236. doi: 10.4103/ijp.ijp_762_20. Indian J Pharmacol. 2023. PMID: 37737075 Free PMC article.
Secondary bacterial infections & extensively drug-resistant bacteria among COVID-19 hospitalized patients at the University Hospital in Kraków.
Pałka A, Kujawska A, Hareza DA, Gajda M, Wordliczek J, Jachowicz-Matczak E, Owsianka I, Żółtowska B, Chmielarczyk A, Romaniszyn D, I GM, Wójkowska-Mach J. Pałka A, et al. Ann Clin Microbiol Antimicrob. 2023 Aug 24;22(1):77. doi: 10.1186/s12941-023-00625-8. Ann Clin Microbiol Antimicrob. 2023. PMID: 37620874 Free PMC article.
Abrupt increased serum creatinine in a hyperferritinemia patient treated with deferoxamine after cord blood transplantation: a case report with literature review.
Nakayama H, Kamoda Y, Tanuma M, Kato T, Usuki K. Nakayama H, et al. J Pharm Health Care Sci. 2023 Jun 1;9(1):18. doi: 10.1186/s40780-023-00287-w. J Pharm Health Care Sci. 2023. PMID: 37259120 Free PMC article.
Adverse Events and Drug Resistance in Critically Ill Patients Treated with Colistimethate Sodium: A Review of the Literature.
Ahumada Topete VH, de Dios Sanchez KJ, Casas Aparicio GA, Hernandez Silva G, Lopez Vejar CE, Torres Espíndola LM, Aquino-Galvez A, Rodriguez Ganen O, Castillejos Lopez MJ. Ahumada Topete VH, et al. Infect Drug Resist. 2023 Mar 10;16:1357-1366. doi: 10.2147/IDR.S398930. eCollection 2023. Infect Drug Resist. 2023. PMID: 36925725 Free PMC article. Review.

References

1. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41. - PubMed
1. Devine, B. 1974. Gentamicin therapy. Drug Intell. Clin. Pharm. 8:650-655.
1. Evans, M. E., D. J. Feola, and R. P. Rapp. 1999. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann. Pharmacother. 33:960-967. - PubMed
1. Falagas, M. E., K. N. Fragoulis, S. K. Kasiakou, G. J. Sermaidis, and A. Michalopoulos. 2005. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int. J. Antimicrob. Agents 26:504-507. - PubMed
1. Falagas, M. E., S. K. Kasiakou, D. P. Kofteridis, G. Roditakis, and G. Samonis. 2006. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 25:596-599. - PubMed

MeSH terms

Substances

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information